Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524
Feline infectious peritonitis (FIP) caused by feline coronavirus (FCoV) is a common dis-ease in cats, fatal if untreated, and no effective treatment is currently legally available. The aim of this study was to evaluate efficacy and toxicity of the multi-component drug Xraphconn<sup>®</sup&g...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2bee380779764fbeb1de77cd1efd14a3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:2bee380779764fbeb1de77cd1efd14a3 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:2bee380779764fbeb1de77cd1efd14a32021-11-25T19:13:32ZCuring Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-44152410.3390/v131122281999-4915https://doaj.org/article/2bee380779764fbeb1de77cd1efd14a32021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4915/13/11/2228https://doaj.org/toc/1999-4915Feline infectious peritonitis (FIP) caused by feline coronavirus (FCoV) is a common dis-ease in cats, fatal if untreated, and no effective treatment is currently legally available. The aim of this study was to evaluate efficacy and toxicity of the multi-component drug Xraphconn<sup>®</sup> in vitro and as oral treatment in cats with spontaneous FIP by examining survival rate, development of clinical and laboratory parameters, viral loads, anti-FCoV antibodies, and adverse effects. Mass spectrometry and nuclear magnetic resonance identified GS-441524 as an active component of Xraphconn<sup>®</sup>. Eighteen cats with FIP were prospectively followed up while being treated orally for 84 days. Values of key parameters on each examination day were compared to values before treatment initiation using linear mixed-effect models. Xraphconn<sup>®</sup> displayed high virucidal activity in cell culture. All cats recovered with dramatic improvement of clinical and laboratory parameters and massive reduction in viral loads within the first few days of treatment without serious adverse effects. Oral treatment with Xraphconn<sup>®</sup> containing GS-441524 was highly effective for FIP without causing serious adverse effects. This drug is an excellent option for the oral treatment of FIP and should be trialed as potential effective treatment option for other severe coronavirus-associated diseases across species.Daniela KrentzKatharina ZengerMartin AlbererSandra FeltenMichèle BergmannRoswitha DorschKaspar MatiasekLaura KolbergRegina Hofmann-LehmannMarina L. MeliAndrea M. SpiriJeannie HorakSaskia WeberCora M. HolickiMartin H. GroschupYury ZablotskiEveline LescrinierBerthold KoletzkoUlrich von BothKatrin HartmannMDPI AGarticleFIPfeline coronavirusFCoVtreatmenttherapyantiviral chemotherapyMicrobiologyQR1-502ENViruses, Vol 13, Iss 2228, p 2228 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
FIP feline coronavirus FCoV treatment therapy antiviral chemotherapy Microbiology QR1-502 |
| spellingShingle |
FIP feline coronavirus FCoV treatment therapy antiviral chemotherapy Microbiology QR1-502 Daniela Krentz Katharina Zenger Martin Alberer Sandra Felten Michèle Bergmann Roswitha Dorsch Kaspar Matiasek Laura Kolberg Regina Hofmann-Lehmann Marina L. Meli Andrea M. Spiri Jeannie Horak Saskia Weber Cora M. Holicki Martin H. Groschup Yury Zablotski Eveline Lescrinier Berthold Koletzko Ulrich von Both Katrin Hartmann Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524 |
| description |
Feline infectious peritonitis (FIP) caused by feline coronavirus (FCoV) is a common dis-ease in cats, fatal if untreated, and no effective treatment is currently legally available. The aim of this study was to evaluate efficacy and toxicity of the multi-component drug Xraphconn<sup>®</sup> in vitro and as oral treatment in cats with spontaneous FIP by examining survival rate, development of clinical and laboratory parameters, viral loads, anti-FCoV antibodies, and adverse effects. Mass spectrometry and nuclear magnetic resonance identified GS-441524 as an active component of Xraphconn<sup>®</sup>. Eighteen cats with FIP were prospectively followed up while being treated orally for 84 days. Values of key parameters on each examination day were compared to values before treatment initiation using linear mixed-effect models. Xraphconn<sup>®</sup> displayed high virucidal activity in cell culture. All cats recovered with dramatic improvement of clinical and laboratory parameters and massive reduction in viral loads within the first few days of treatment without serious adverse effects. Oral treatment with Xraphconn<sup>®</sup> containing GS-441524 was highly effective for FIP without causing serious adverse effects. This drug is an excellent option for the oral treatment of FIP and should be trialed as potential effective treatment option for other severe coronavirus-associated diseases across species. |
| format |
article |
| author |
Daniela Krentz Katharina Zenger Martin Alberer Sandra Felten Michèle Bergmann Roswitha Dorsch Kaspar Matiasek Laura Kolberg Regina Hofmann-Lehmann Marina L. Meli Andrea M. Spiri Jeannie Horak Saskia Weber Cora M. Holicki Martin H. Groschup Yury Zablotski Eveline Lescrinier Berthold Koletzko Ulrich von Both Katrin Hartmann |
| author_facet |
Daniela Krentz Katharina Zenger Martin Alberer Sandra Felten Michèle Bergmann Roswitha Dorsch Kaspar Matiasek Laura Kolberg Regina Hofmann-Lehmann Marina L. Meli Andrea M. Spiri Jeannie Horak Saskia Weber Cora M. Holicki Martin H. Groschup Yury Zablotski Eveline Lescrinier Berthold Koletzko Ulrich von Both Katrin Hartmann |
| author_sort |
Daniela Krentz |
| title |
Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524 |
| title_short |
Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524 |
| title_full |
Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524 |
| title_fullStr |
Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524 |
| title_full_unstemmed |
Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524 |
| title_sort |
curing cats with feline infectious peritonitis with an oral multi-component drug containing gs-441524 |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/2bee380779764fbeb1de77cd1efd14a3 |
| work_keys_str_mv |
AT danielakrentz curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT katharinazenger curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT martinalberer curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT sandrafelten curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT michelebergmann curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT roswithadorsch curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT kasparmatiasek curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT laurakolberg curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT reginahofmannlehmann curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT marinalmeli curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT andreamspiri curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT jeanniehorak curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT saskiaweber curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT coramholicki curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT martinhgroschup curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT yuryzablotski curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT evelinelescrinier curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT bertholdkoletzko curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT ulrichvonboth curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 AT katrinhartmann curingcatswithfelineinfectiousperitonitiswithanoralmulticomponentdrugcontaininggs441524 |
| _version_ |
1718410143198085120 |